22 Jul 2013 07:00
News Release
22 July 2013
Consort Medical plc
Bespak development contract award
Consort Medical plc ("Consort" or "The Group") (LSE: CSRT), announces the award of a new device development contract.
Bespak's Cambridge based Innovation Team have developed a novel, patented nasal drug delivery device, and the customer has contracted with Bespak to develop this for use in this specific application.
The contract win, the details of which are confidential, adds to Consort Medical's Development pipeline, as programme NAS030. The programme may include drug handling.
Jonathan Glenn, Consort Medical Chief Executive commented: "We are delighted to have secured this contract in an exciting therapeutic area, and are pleased with the latest success of our Innovation team which was created approximately three years ago. The programme award represents the continued execution of our organic diversified growth strategy, further broadening the portfolio."
Consort Medical will publish its Annual report on 25 July 2013, ahead of its AGM on 2 September 2013. Consort's Q1 IMS will be released on 2 September 2013.
-Ends-
Enquiries:
ConsortJonathan Glenn - Chief Executive Richard Cotton - Finance Director | Tel: +44 1442 867920 |
Brunswick Group Jon Coles Anna Carruth | Tel: +44 20 7404 5959
|
Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
The Group has facilities in King's Lynn, Cambridge, Nelson and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.